Ten Pharma Firms Form Non-profit to Speed Up New Drug Trials; InBalance Health Launches New Nutrition Bars; Novo Nordisk Ranks High on Carbon Disclosure Project - Health Minute for September 27, 2012
Ten pharmaceutical companies from the U.S. and Europe have formed a nonprofit to accelerate the development of new drugs. The organization, TransCelerate BioPharma, will be headquartered in Philadelphia. The founding companies are Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche Holding AG’s Genentech, and Sanofi SA.
InBalance Health, a company that provides doctor-formulated, alternative food bar and supplement solutions for prediabetes and Type 2 diabetes patients, has announced its launch and new healthy snack products. The company’s INbars are allergen-free and offer whole food nutrients, and are also useful for people with weight-loss or glucose management goals.
Novo Nordisk has been ranked in the top 10 of healthcare companies in the Carbon Disclosure Project’s Global 500 2012 report. Compared to 2011, Novo Nordisk improved its score by 1 to 90 out of 100. According to the CDP, the score shows that the company has recognized climate change as a priority for strategy.
For more information on these and other stories, go to 3blmedia.com